These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 35357653)

  • 1. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
    Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
    Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
    Shadman M
    JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Odetola O; Ma S
    Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
    Smolewski P; Robak T
    Acta Haematol; 2021; 144(4):365-379. PubMed ID: 33238270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
    Montoya S; Thompson MC
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
    Wiedmeier-Nutor J; Leis J
    Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Alsouqi A; Woyach JA
    Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38897870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
    Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA
    J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Javidi-Sharifi N; Brown JR
    Expert Rev Hematol; 2024 Jun; 17(6):201-210. PubMed ID: 38784995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
    Robak T; Witkowska M; Smolewski P
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
    Bose P; Gandhi V
    Fac Rev; 2021; 10():22. PubMed ID: 33718939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages.
    Robak P; Robak T
    Expert Opin Biol Ther; 2023 Jan; 23(1):21-35. PubMed ID: 36374125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
    N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.
    Hatashima A; Shadman M
    Expert Rev Hematol; 2024 Oct; 17(10):687-703. PubMed ID: 39163531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
    Bennett R; Seymour JF
    Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Easaw S; Ezzati S; Coombs CC
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.